{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:49:47Z","timestamp":1740142187656,"version":"3.37.3"},"reference-count":99,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation Project of Jiangsu Province","doi-asserted-by":"publisher","award":["17KJB310001"],"award-info":[{"award-number":["17KJB310001"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Health Commission of Jiangsu Province","doi-asserted-by":"publisher","award":["LGY2018025"],"award-info":[{"award-number":["LGY2018025"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018592","name":"333 project funding plan","doi-asserted-by":"publisher","award":["BRA2019172"],"award-info":[{"award-number":["BRA2019172"]}],"id":[{"id":"10.13039\/501100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Cellular metabolic reprogramming driven by oncogenic mutations is considered as a hallmark\nin the development of malignant cells, and has been a focus over the past decade. A common\ntheme emerging from these metabolic alterations is that tumor cells can acquire necessary nutrients\nfrom a nutrient-limited microenvironment and utilize them to sustain growth and unrestrained cellular\ndivision. However, this significant metabolic flexibility and the hostile microenvironment caused by the\ninsufficient vascular exchange, depletion of nutrients, hypoxia, and accumulation of waste products, can\ninhibit the metabolism and immune activity of tumor-infiltrating lymphocytes and impose barriers to\neffective antitumor immunotherapies. In this perspective, we review the classical alterations in tumorigenesis-\nassociated metabolic reprogramming and examine the functional contribution of these aberrant\nmetabolisms to the establishment and maintenance of an immunosuppressive microenvironment. Furthermore,\nwe explore the possible approaches to targeting on these metabolic pathways to achieve antitumor\nimmunotherapy, as well as some hypothetical or ongoing combination therapeutic strategies that\ncould, to a certain extent, biologically rationalize and broaden the utility of immune checkpoint inhibitors.\nUltimately, we elucidate some dietary modifications that can limit tumor-specific nutritional requirements\nand maximize the cytotoxicity of other antineoplastic drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389203723666220620161742","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T06:44:23Z","timestamp":1655793863000},"page":"585-601","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Manipulating Metabolic Alterations and their Consequences to Unleash the Potential of Antitumor Immunotherapy"],"prefix":"10.2174","volume":"23","author":[{"given":"Yan","family":"Wu","sequence":"first","affiliation":[{"name":"The Fourth Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu, China"},{"name":"School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu, China"},{"name":"School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu, China"},{"name":"School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"Pavlova N.N.","year":"2016","unstructured":"Pavlova N.N.; Thompson C.B.; The emerging hallmarks of cancer metabolism. Cell Metab 2016,23(1),27-47","journal-title":"Cell Metab"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"Warburg O.","year":"1956","unstructured":"Warburg O.; On the origin of cancer cells. Science 1956,123(3191),309-314","journal-title":"Science"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.devcel.2016.02.012","volume":"36","author":"Hosios A.M.","year":"2016","unstructured":"Hosios A.M.; Hecht V.C.; Danai L.V.; Johnson M.O.; Rathmell J.C.; Steinhauser M.L.; Manalis S.R.; Vander Heiden M.G.; Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell 2016,36(5),540-549","journal-title":"Dev Cell"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/onc.2009.358","volume":"29","author":"DeBerardinis R.J.","year":"2010","unstructured":"DeBerardinis R.J.; Cheng T.; Q\u2019s next: The diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010,29(3),313-324","journal-title":"Oncogene"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1126\/science.aaf5171","volume":"353","author":"Mayers J.R.","year":"2016","unstructured":"Mayers J.R.; Torrence M.E.; Danai L.V.; Papagiannakopoulos T.; Davidson S.M.; Bauer M.R.; Lau A.N.; Ji B.W.; Dixit P.D.; Hosios A.M.; Muir A.; Chin C.R.; Freinkman E.; Jacks T.; Wolpin B.M.; Vitkup D.; Vander Heiden M.G.; Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 2016,353(6304),1161-1165","journal-title":"Science"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.plipres.2013.08.005","volume":"52","author":"Zaidi N.","year":"2013","unstructured":"Zaidi N.; Lupien L.; Kuemmerle N.B.; Kinlaw W.B.; Swinnen J.V.; Smans K.; Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res 2013,52(4),585-589","journal-title":"Prog Lipid Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"Menendez J.A.","year":"2007","unstructured":"Menendez J.A.; Lupu R.; Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007,7(10),763-777","journal-title":"Nat Rev Cancer"},{"key":"ref=8","first-page":"515","volume":"2","author":"Wang C.","year":"2010","unstructured":"Wang C.; Rajput S.; Watabe K.; Liao D.F.; Cao D.; Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci (Schol Ed) 2010,2(2),515-526","journal-title":"Front Biosci (Schol Ed)"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-020-00320-2","volume":"21","author":"Bergers G.","year":"2021","unstructured":"Bergers G.; Fendt S.M.; The metabolism of cancer cells during metastasis. Nat Rev Cancer 2021,21(3),162-180","journal-title":"Nat Rev Cancer"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1126\/science.303.5663.1454","volume":"303","author":"Marx J.","year":"2004","unstructured":"Marx J.; Cell biology. How cells endure low oxygen. Science 2004,303(5663),1454-1456","journal-title":"Science"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.celrep.2019.03.029","volume":"27","author":"Miska J.","year":"2019","unstructured":"Miska J.; Lee-Chang C.; Rashidi A.; Muroski M.E.; Chang A.L.; Lopez-Rosas A.; Zhang P.; Panek W.K.; Cordero A.; Han Y.; Ahmed A.U.; Chandel N.S.; Lesniak M.S.; HIF-1\u03b1 is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of tregs in glioblastoma. Cell Rep 2019,27(1),226-237","journal-title":"Cell Rep"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"143729","DOI":"10.1172\/JCI143729","volume":"131","author":"Liikanen I.","year":"2021","unstructured":"Liikanen I.; Lauhan C.; Quon S.; Omilusik K.; Phan A.T.; Bartrol\u00ed L.B.; Ferry A.; Goulding J.; Chen J.; Scott-Browne J.P.; Yustein J.T.; Scharping N.E.; Witherden D.A.; Goldrath A.W.; Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. J Clin Invest 2021,131(7),143729","journal-title":"J Clin Invest"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"Noman M.Z.","year":"2014","unstructured":"Noman M.Z.; Desantis G.; Janji B.; Hasmim M.; Karray S.; Dessen P.; Bronte V.; Chouaib S.; PD-L1 is a novel direct target of HIF-1\u03b1 and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014,211(5),781-790","journal-title":"J Exp Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"Scharping N.E.","year":"2021","unstructured":"Scharping N.E.; Rivadeneira D.B.; Menk A.V.; Vignali P.D.A.; Ford B.R.; Rittenhouse N.L.; Peralta R.; Wang Y.; Wang Y.; DePeaux K.; Poholek A.C.; Delgoffe G.M.; Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol 2021,22(2),205-215","journal-title":"Nat Immunol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","volume":"153","author":"Chang C.H.","year":"2013","unstructured":"Chang C.H.; Curtis J.D.; Maggi L.B.; Faubert B.; Villarino A.V.; O\u2019Sullivan D.; Huang S.C.; van der Windt G.J.; Blagih J.; Qiu J.; Weber J.D.; Pearce E.J.; Jones R.G.; Pearce E.L.; Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013,153(6),1239-1251","journal-title":"Cell"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nrm2972","volume":"11","author":"Buchakjian M.R.","year":"2010","unstructured":"Buchakjian M.R.; Kornbluth S.; The engine driving the ship: Metabolic steering of cell proliferation and death. Nat Rev Mol Cell Biol 2010,11(10),715-727","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","volume":"162","author":"Ho P.C.","year":"2015","unstructured":"Ho P.C.; Bihuniak J.D.; Macintyre A.N.; Staron M.; Liu X.; Amezquita R.; Tsui Y.C.; Cui G.; Micevic G.; Perales J.C.; Kleinstein S.H.; Abel E.D.; Insogna K.L.; Feske S.; Locasale J.W.; Bosenberg M.W.; Rathmell J.C.; Kaech S.M.; Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 2015,162(6),1217-1228","journal-title":"Cell"},{"key":"ref=18","first-page":"916","volume":"60","author":"Walenta S.","year":"2000","unstructured":"Walenta S.; Wetterling M.; Lehrke M.; Schwickert G.; Sundf\u00f8r K.; Rofstad E.K.; Mueller-Klieser W.; High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000,60(4),916-921","journal-title":"Cancer Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.imlet.2015.07.003","volume":"167","author":"Nakagawa Y.","year":"2015","unstructured":"Nakagawa Y.; Negishi Y.; Shimizu M.; Takahashi M.; Ichikawa M.; Takahashi H.; Effects of extracellular pH and hypoxia on the function and development of antigen-specific cytotoxic T lymphocytes. Immunol Lett 2015,167(2),72-86","journal-title":"Immunol Lett"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","volume":"72","author":"Calcinotto A.","year":"2012","unstructured":"Calcinotto A.; Filipazzi P.; Grioni M.; Iero M.; De Milito A.; Ricupito A.; Cova A.; Canese R.; Jachetti E.; Rossetti M.; Huber V.; Parmiani G.; Generoso L.; Santinami M.; Borghi M.; Fais S.; Bellone M.; Rivoltini L.; Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 2012,72(11),2746-2756","journal-title":"Cancer Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","volume":"76","author":"Pilon-Thomas S.","year":"2016","unstructured":"Pilon-Thomas S.; Kodumudi K.N.; El-Kenawi A.E.; Russell S.; Weber A.M.; Luddy K.; Damaghi M.; Wojtkowiak J.W.; Mul\u00e9 J.J.; Ibrahim-Hashim A.; Gillies R.J.; Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res 2016,76(6),1381-1390","journal-title":"Cancer Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1021\/acs.nanolett.8b04296","volume":"19","author":"Zhang Y.X.","year":"2019","unstructured":"Zhang Y.X.; Zhao Y.Y.; Shen J.; Sun X.; Liu Y.; Liu H.; Wang Y.; Wang J.; Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating t cells and potentiates anti-PD-1 therapy. Nano Lett 2019,19(5),2774-2783","journal-title":"Nano Lett"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","volume":"37","author":"Munn D.H.","year":"2016","unstructured":"Munn D.H.; Mellor A.L.; IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance. Trends Immunol 2016,37(3),193-207","journal-title":"Trends Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/ni1003","volume":"4","author":"Fallarino F.","year":"2003","unstructured":"Fallarino F.; Grohmann U.; Hwang K.W.; Orabona C.; Vacca C.; Bianchi R.; Belladonna M.L.; Fioretti M.C.; Alegre M.L.; Puccetti P.; Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003,4(12),1206-1212","journal-title":"Nat Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","volume":"33","author":"Liu Y.","year":"2018","unstructured":"Liu Y.; Liang X.; Dong W.; Fang Y.; Lv J.; Zhang T.; Fiskesund R.; Xie J.; Liu J.; Yin X.; Jin X.; Chen D.; Tang K.; Ma J.; Zhang H.; Yu J.; Yan J.; Liang H.; Mo S.; Cheng F.; Zhou Y.; Zhang H.; Wang J.; Li J.; Chen Y.; Cui B.; Hu Z.W.; Cao X.; Xiao-Feng Qin.; F.; Huang, B. Tumor-repopulating cells induce PD-1 expression in CD8+ T cells by transferring kynurenine and AhR activation. Cancer Cell 2018,33(3),480-494","journal-title":"Cancer Cell"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","volume":"10","author":"Vigano S.","year":"2019","unstructured":"Vigano S.; Alatzoglou D.; Irving M.; M\u00e9n\u00e9trier-Caux C.; Caux C.; Romero P.; Coukos G.; Targeting adenosine in cancer immunotherapy to enhance T-Cell function. Front Immunol 2019,10,925","journal-title":"Front Immunol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijsu.2020.05.019","volume":"79","author":"Zhang N.","year":"2020","unstructured":"Zhang N.; Zhang H.; Zhu D.; JiRiGaLa; Yu, D.; Wang, C.; WuYunBiLiGe; Amin; ZhiHong; Yu, H.; Chen, X.; Wang, M. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: A systematic review and meta-analysis. Int J Surg 2020,79,66-73","journal-title":"Int J Surg"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00432-019-02847-w","volume":"145","author":"Yu M.","year":"2019","unstructured":"Yu M.; Chen S.; Hong W.; Gu Y.; Huang B.; Lin Y.; Zhou Y.; Jin H.; Deng Y.; Tu L.; Hou B.; Jian Z.; Prognostic role of glycolysis for cancer outcome: Evidence from 86 studies. J Cancer Res Clin Oncol 2019,145(4),967-999","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/neuonc\/noq080","volume":"12","author":"Kefas B.","year":"2010","unstructured":"Kefas B.; Comeau L.; Erdle N.; Montgomery E.; Amos S.; Purow B.; Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro-oncol 2010,12(11),1102-1112","journal-title":"Neuro-oncol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13020-019-0231-3","volume":"14","author":"Wang Z.","year":"2019","unstructured":"Wang Z.; Yin J.; Li M.; Shen J.; Xiao Z.; Zhao Y.; Huang C.; Zhang H.; Zhang Z.; Cho C.H.; Wu X.; Combination of shikonin with paclitaxel overcomes multidrug resistance in human ovarian carcinoma cells in a P-gp-independent manner through enhanced ROS generation. Chin Med 2019,14(1),7","journal-title":"Chin Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3389\/fimmu.2017.01300","volume":"8","author":"Palsson-McDermott E.M.","year":"2017","unstructured":"Palsson-McDermott E.M.; Dyck L.; Zas\u0142ona, Z.; Menon, D.; McGettrick, A.F.; Mills, K.H.G.; O\u2019Neill, L.A. Pyruvate kinase M2 is required for the expression of the immune Checkpoint PD-L1 in immune cells and tumors. Front Immunol 2017,8,1300","journal-title":"Front Immunol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molmet.2019.07.006","volume":"33","author":"Payen V.L.","year":"2020","unstructured":"Payen V.L.; Mina E.; Van H\u00e9e V.F.; Porporato P.E.; Sonveaux P.; Monocarboxylate transporters in cancer. Mol Metab 2020,33,48-66","journal-title":"Mol Metab"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1158\/1535-7163.MCT-17-1253","volume":"17","author":"Quanz M.","year":"2018","unstructured":"Quanz M.; Bender E.; Kopitz C.; Gr\u00fcnewald S.; Schlicker A.; Schwede W.; Eheim A.; Toschi L.; Neuhaus R.; Richter C.; Toedling J.; Merz C.; Lesche R.; Kamburov A.; Siebeneicher H.; Bauser M.; H\u00e4gebarth A.; Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance. Mol Cancer Ther 2018,17(11),2285-2296","journal-title":"Mol Cancer Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1021\/jm980334n","volume":"41","author":"Deck L.M.","year":"1998","unstructured":"Deck L.M.; Royer R.E.; Chamblee B.B.; Hernandez V.M.; Malone R.R.; Torres J.E.; Hunsaker L.A.; Piper R.C.; Makler M.T.; Vander Jagt D.L.; Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite Plasmodium falciparum. J Med Chem 1998,41(20),3879-3887","journal-title":"J Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","volume":"27","author":"Cascone T.","year":"2018","unstructured":"Cascone T.; McKenzie J.A.; Mbofung R.M.; Punt S.; Wang Z.; Xu C.; Williams L.J.; Wang Z.; Bristow C.A.; Carugo A.; Peoples M.D.; Li L.; Karpinets T.; Huang L.; Malu S.; Creasy C.; Leahey S.E.; Chen J.; Chen Y.; Pelicano H.; Bernatchez C.; Gopal Y.N.V.; Heffernan T.P.; Hu J.; Wang J.; Amaria R.N.; Garraway L.A.; Huang P.; Yang P.; Wistuba I.I.; Woodman S.E.; Roszik J.; Davis R.E.; Davies M.A.; Heymach J.V.; Hwu P.; Peng W.; Increased tumor glycolysis characterizes immune resistance to adoptive t cell therapy. Cell Metab 2018,27(5),977-987","journal-title":"Cell Metab"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"Weide B.","year":"2016","unstructured":"Weide B.; Martens A.; Hassel J.C.; Berking C.; Postow M.A.; Bisschop K.; Simeone E.; Mangana J.; Schilling B.; Di Giacomo A.M.; Brenner N.; K\u00e4hler K.; Heinzerling L.; Gutzmer R.; Bender A.; Gebhardt C.; Romano E.; Meier F.; Martus P.; Maio M.; Blank C.; Schadendorf D.; Dummer R.; Ascierto P.A.; Hospers G.; Garbe C.; Wolchok J.D.; Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 2016,22(22),5487-5496","journal-title":"Clin Cancer Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/1535-7163.MCT-19-0079","volume":"18","author":"Woolbright B.L.","year":"2019","unstructured":"Woolbright B.L.; Rajendran G.; Harris R.A.; Taylor J.A.; Metabolic flexibility in cancer: Targeting the pyruvate dehydrogenase kinase: Pyruvate dehydrogenase Axis. Mol Cancer Ther 2019,18(10),1673-1681","journal-title":"Mol Cancer Ther"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41577-019-0256-y","volume":"20","author":"Bordon Y.","year":"2020","unstructured":"Bordon Y.; T cell flexibility points to a metabolic checkpoint for cancer therapy. Nat Rev Immunol 2020,20(1),2-3","journal-title":"Nat Rev Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1172\/JCI131859","volume":"130","author":"Oh M.H.","year":"2020","unstructured":"Oh M.H.; Sun I.H.; Zhao L.; Leone R.D.; Sun I.M.; Xu W.; Collins S.L.; Tam A.J.; Blosser R.L.; Patel C.H.; Englert J.M.; Arwood M.L.; Wen J.; Chan-Li Y.; Tenora L.; Majer P.; Rais R.; Slusher B.S.; Horton M.R.; Powell J.D.; Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest 2020,130(7),3865-3884","journal-title":"J Clin Invest"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1021\/acs.jmedchem.8b00961","volume":"62","author":"Xu X.","year":"2019","unstructured":"Xu X.; Meng Y.; Li L.; Xu P.; Wang J.; Li Z.; Bian J.; Overview of the development of glutaminase inhibitors: Achievements and future directions. J Med Chem 2019,62(3),1096-1115","journal-title":"J Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"589508","DOI":"10.3389\/fonc.2020.589508","volume":"10","author":"Wang Z.","year":"2020","unstructured":"Wang Z.; Liu F.; Fan N.; Zhou C.; Li D.; Macvicar T.; Dong Q.; Bruns C.J.; Zhao Y.; Targeting glutaminolysis: New perspectives to understand cancer development and novel strategies for potential target therapies. Front Oncol 2020,10,589508","journal-title":"Front Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","volume":"16","author":"Li X.","year":"2019","unstructured":"Li X.; Wenes M.; Romero P.; Huang S.C.; Fendt S.M.; Ho P.C.; Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol 2019,16(7),425-441","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.molcel.2020.10.015","volume":"80","author":"Byun J.K.","year":"2020","unstructured":"Byun J.K.; Park M.; Lee S.; Yun J.W.; Lee J.; Kim J.S.; Cho S.J.; Jeon H.J.; Lee I.K.; Choi Y.K.; Park K.G.; Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity. Mol Cell 2020,80(4),592-606","journal-title":"Mol Cell"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/15384047.2016.1276136","volume":"18","author":"He X.","year":"2017","unstructured":"He X.; Lin H.; Yuan L.; Li B.; Combination therapy with L-arginine and \u03b1-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice. Cancer Biol Ther 2017,18(2),94-100","journal-title":"Cancer Biol Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"E4234","DOI":"10.3390\/ijms21124234","volume":"21","author":"Chung S.F.","year":"2020","unstructured":"Chung S.F.; Kim C.F.; Kwok S.Y.; Tam S.Y.; Chen Y.W.; Chong H.C.; Leung S.L.; So P.K.; Wong K.Y.; Leung Y.C.; Lo W.H.; Mono-PEGylation of a thermostable arginine-depleting enzyme for the treatment of lung cancer. Int J Mol Sci 2020,21(12),E4234","journal-title":"Int J Mol Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1158\/1078-0432.CCR-19-1905","volume":"26","author":"Ji J.X.","year":"2020","unstructured":"Ji J.X.; Cochrane D.R.; Tessier-Cloutier B.; Chen S.Y.; Ho G.; Pathak K.V.; Alcazar I.N.; Farnell D.; Leung S.; Cheng A.; Chow C.; Colborne S.; Negri G.L.; Kommoss F.; Karnezis A.; Morin G.B.; McAlpine J.N.; Gilks C.B.; Weissman B.E.; Trent J.M.; Hoang L.; Pirrotte P.; Wang Y.; Huntsman D.G.; Arginine Depletion Therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase-deficient ovarian cancer, including small-cell carcinoma of the ovary, hypercalcemic type. Clin Cancer Res 2020,26(16),4402-4413","journal-title":"Clin Cancer Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"58948","DOI":"10.18632\/oncotarget.19564","volume":"8","author":"Brin E.","year":"2017","unstructured":"Brin E.; Wu K.; Lu H.T.; He Y.; Dai Z.; He W.; PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. Oncotarget 2017,8(35),58948-58963","journal-title":"Oncotarget"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s13577-020-00437-4","volume":"34","author":"Swayden M.","year":"2021","unstructured":"Swayden M.; Bekdash A.; Fakhoury I.; El-Atat O.; Borjac-Natour J.; El-Sibai M.; Abi-Habib R.J.; Activation of autophagy following [HuArgI (Co)-PEG5000]-induced arginine deprivation mediates cell death in colon cancer cells. Hum Cell 2021,34(1),152-164","journal-title":"Hum Cell"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3389\/fimmu.2020.00938","volume":"11","author":"Grzywa T.M.","year":"2020","unstructured":"Grzywa T.M.; Sosnowska A.; Matryba P.; Rydzynska Z.; Jasinski M.; Nowis D.; Golab J.; Myeloid cell-derived arginase in cancer immune response. Front Immunol 2020,11,938","journal-title":"Front Immunol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"152383","DOI":"10.1016\/j.prp.2019.03.012","volume":"215","author":"Ma Z.","year":"2019","unstructured":"Ma Z.; Lian J.; Yang M.; Wuyang J.; Zhao C.; Chen W.; Liu C.; Zhao Q.; Lou C.; Han J.; Zhang Y.; Overexpression of Arginase-1 is an indicator of poor prognosis in patients with colorectal cancer. Pathol Res Pract 2019,215(6),152383","journal-title":"Pathol Res Pract"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/med.21419","volume":"37","author":"Pudlo M.","year":"2017","unstructured":"Pudlo M.; Demougeot C.; Girard-Thernier C.; Arginase inhibitors: A rational approach over one century. Med Res Rev 2017,37(3),475-513","journal-title":"Med Res Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","volume":"5","author":"Steggerda S.M.","year":"2017","unstructured":"Steggerda S.M.; Bennett M.K.; Chen J.; Emberley E.; Huang T.; Janes J.R.; Li W.; MacKinnon A.L.; Makkouk A.; Marguier G.; Murray P.J.; Neou S.; Pan A.; Parlati F.; Rodriguez M.L.M.; Van de Velde L.A.; Wang T.; Works M.; Zhang J.; Zhang W.; Gross M.I.; Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer 2017,5(1),101","journal-title":"J Immunother Cancer"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/acsmedchemlett.9b00508","volume":"11","author":"Blaszczyk R.","year":"2020","unstructured":"Blaszczyk R.; Brzezinska J.; Dymek B.; Stanczak P.S.; Mazurkiewicz M.; Olczak J.; Nowicka J.; Dzwonek K.; Zagozdzon A.; Golab J.; Golebiowski A.; Discovery and pharmacokinetics of sulfamides and guanidines as potent human arginase 1 inhibitors. ACS Med Chem Lett 2020,11(4),433-438","journal-title":"ACS Med Chem Lett"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/s41467-019-10979-3","volume":"10","author":"Czystowska-Kuzmicz M.","year":"2019","unstructured":"Czystowska-Kuzmicz M.; Sosnowska A.; Nowis D.; Ramji K.; Szajnik M.; Chlebowska-Tuz J.; Wolinska E.; Gaj P.; Grazul M.; Pilch Z.; Zerrouqi A.; Graczyk-Jarzynka A.; Soroczynska K.; Cierniak S.; Koktysz R.; Elishaev E.; Gruca S.; Stefanowicz A.; Blaszczyk R.; Borek B.; Gzik A.; Whiteside T.; Golab J.; Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun 2019,10(1),3000","journal-title":"Nat Commun"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"eaaf9794","DOI":"10.1126\/science.aaf9794","volume":"357","author":"Cervenka I.","year":"2017","unstructured":"Cervenka I.; Agudelo L.Z.; Ruas J.L.; Kynurenines: Tryptophan\u2019s metabolites in exercise, inflammation, and mental health. Science 2017,357(6349),eaaf9794","journal-title":"Science"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-019-0106-z","volume":"19","author":"Lemos H.","year":"2019","unstructured":"Lemos H.; Huang L.; Prendergast G.C.; Mellor A.L.; Immune control by amino acid catabolism during tumorigenesis and therapy. Nat Rev Cancer 2019,19(3),162-175","journal-title":"Nat Rev Cancer"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"Platten M.","year":"2019","unstructured":"Platten M.; Nollen E.A.A.; R\u00f6hrig U.F.; Fallarino F.; Opitz C.A.; Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov 2019,18(5),379-401","journal-title":"Nat Rev Drug Discov"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"710","DOI":"10.4103\/0366-6999.201613","volume":"130","author":"Zhang T.","year":"2017","unstructured":"Zhang T.; Tan X.L.; Xu Y.; Wang Z.Z.; Xiao C.H.; Liu R.; Expression and prognostic value of Indoleamine 2,3-dioxygenase in pancreatic cancer. Chin Med J (Engl) 2017,130(6),710-716","journal-title":"Chin Med J (Engl)"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","volume":"9","author":"Le Naour J.","year":"2020","unstructured":"Le Naour J.; Galluzzi L.; Zitvogel L.; Kroemer G.; Vacchelli E.; Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 2020,9(1),1777625","journal-title":"OncoImmunology"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41416-019-0664-6","volume":"122","author":"Opitz C.A.","year":"2020","unstructured":"Opitz C.A.; Somarribas Patterson L.F.; Mohapatra S.R.; Dewi D.L.; Sadik A.; Platten M.; Trump S.; The therapeutic potential of targeting tryptophan catabolism in cancer. Br J Cancer 2020,122(1),30-44","journal-title":"Br J Cancer"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","volume":"14","author":"Nishino M.","year":"2017","unstructured":"Nishino M.; Ramaiya N.H.; Hatabu H.; Hodi F.S.; Monitoring immune-checkpoint blockade: Response evaluation and biomarker development. Nat Rev Clin Oncol 2017,14(11),655-668","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e1424674","DOI":"10.1080\/2162402X.2018.1424674","volume":"7","author":"Kverneland A.H.","year":"2018","unstructured":"Kverneland A.H.; Enevold C.; Donia M.; Bastholt L.; Svane I.M.; Nielsen C.H.; Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. OncoImmunology 2018,7(5),e1424674","journal-title":"OncoImmunology"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-019-0562-8","volume":"7","author":"Gibney G.T.","year":"2019","unstructured":"Gibney G.T.; Hamid O.; Lutzky J.; Olszanski A.J.; Mitchell T.C.; Gajewski T.F.; Chmielowski B.; Hanks B.A.; Zhao Y.; Newton R.C.; Maleski J.; Leopold L.; Weber J.S.; Phase 1\/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer 2019,7(1),80","journal-title":"J Immunother Cancer"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"Long G.V.","year":"2019","unstructured":"Long G.V.; Dummer R.; Hamid O.; Gajewski T.F.; Caglevic C.; Dalle S.; Arance A.; Carlino M.S.; Grob J-J.; Kim T.M.; Demidov L.; Robert C.; Larkin J.; Anderson J.R.; Maleski J.; Jones M.; Diede S.J.; Mitchell T.C.; Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): A phase 3, randomised, double-blind study. Lancet Oncol 2019,20(8),1083-1097","journal-title":"Lancet Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10637-019-00787-3","volume":"38","author":"Ebata T.","year":"2020","unstructured":"Ebata T.; Shimizu T.; Fujiwara Y.; Tamura K.; Kondo S.; Iwasa S.; Yonemori K.; Shimomura A.; Kitano S.; Koyama T.; Sato N.; Nakai K.; Inatani M.; Yamamoto N.; Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours. Invest New Drugs 2020,38(2),468-477","journal-title":"Invest New Drugs"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1126\/science.360.6389.588","volume":"360","author":"Garber K.","year":"2018","unstructured":"Garber K.; A new cancer immunotherapy suffers a setback. American Association for the Advancement of Science 2018,360(6389),588","journal-title":"American Association for the Advancement of Science"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ccell.2017.11.011","volume":"32","author":"Guri Y.","year":"2017","unstructured":"Guri Y.; Colombi M.; Dazert E.; Hindupur S.K.; Roszik J.; Moes S.; Jenoe P.; Heim M.H.; Riezman I.; Riezman H.; Hall M.N.; mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell 2017,32(6),807-823","journal-title":"Cancer Cell"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pharmthera.2017.02.021","volume":"177","author":"Buckley D.","year":"2017","unstructured":"Buckley D.; Duke G.; Heuer T.S.; O\u2019Farrell M.; Wagman A.S.; McCulloch W.; Kemble G.; Fatty acid synthase - Modern tumor cell biology insights into a classical oncology target. Pharmacol Ther 2017,177,23-31","journal-title":"Pharmacol Ther"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"24787","DOI":"10.18632\/oncotarget.25361","volume":"9","author":"Zaytseva Y.Y.","year":"2018","unstructured":"Zaytseva Y.Y.; Rychahou P.G.; Le A.T.; Scott T.L.; Flight R.M.; Kim J.T.; Harris J.; Liu J.; Wang C.; Morris A.J.; Sivakumaran T.A.; Fan T.; Moseley H.; Gao T.; Lee E.Y.; Weiss H.L.; Heuer T.S.; Kemble G.; Evers M.; Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget 2018,9(37),24787-24800","journal-title":"Oncotarget"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"Falchook G.","year":"2021","unstructured":"Falchook G.; Infante J.; Arkenau H.T.; Patel M.R.; Dean E.; Borazanci E.; Brenner A.; Cook N.; Lopez J.; Pant S.; Frankel A.; Schmid P.; Moore K.; McCulloch W.; Grimmer K.; O\u2019Farrell M.; Kemble G.; Burris H.; First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine 2021,34,100797","journal-title":"EClinicalMedicine"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1158\/0008-5472.CAN-09-3228","volume":"70","author":"Lee C.","year":"2010","unstructured":"Lee C.; Safdie F.M.; Raffaghello L.; Wei M.; Madia F.; Parrella E.; Hwang D.; Cohen P.; Bianchi G.; Longo V.D.; Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res 2010,70(4),1564-1572","journal-title":"Cancer Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/onc.2017.398","volume":"37","author":"Ma D.","year":"2018","unstructured":"Ma D.; Chen X.; Zhang P.Y.; Zhang H.; Wei L.J.; Hu S.; Tang J.Z.; Zhou M.T.; Xie C.; Ou R.; Xu Y.; Tang K.F.; Upregulation of the ALDOA\/DNA-PK\/p53 pathway by dietary restriction suppresses tumor growth. Oncogene 2018,37(8),1041-1048","journal-title":"Oncogene"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cmet.2015.05.012","volume":"22","author":"Brandhorst S.","year":"2015","unstructured":"Brandhorst S.; Choi I.Y.; Wei M.; Cheng C.W.; Sedrakyan S.; Navarrete G.; Dubeau L.; Yap L.P.; Park R.; Vinciguerra M.; Di Biase S.; Mirzaei H.; Mirisola M.G.; Childress P.; Ji L.; Groshen S.; Penna F.; Odetti P.; Perin L.; Conti P.S.; Ikeno Y.; Kennedy B.K.; Cohen P.; Morgan T.E.; Dorff T.B.; Longo V.D.; A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab 2015,22(1),86-99","journal-title":"Cell Metab"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13046-019-1189-9","volume":"38","author":"de Groot S.","year":"2019","unstructured":"de Groot S.; Pijl H.; van der Hoeven J.J.M.; Kroep J.R.; Effects of short-term fasting on cancer treatment. J Exp Clin Cancer Res 2019,38(1),209","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.4049\/jimmunol.0900562","volume":"183","author":"Yang H.","year":"2009","unstructured":"Yang H.; Youm Y.H.; Dixit V.D.; Inhibition of thymic adipogenesis by caloric restriction is coupled with reduction in age-related thymic involution. J Immunol 2009,183(5),3040-3052","journal-title":"J Immunol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"19448","DOI":"10.1073\/pnas.0606661103","volume":"103","author":"Messaoudi I.","year":"2006","unstructured":"Messaoudi I.; Warner J.; Fischer M.; Park B.; Hill B.; Mattison J.; Lane M.A.; Roth G.S.; Ingram D.K.; Picker L.J.; Douek D.C.; Mori M.; Nikolich-Zugich J.; Delay of T cell senescence by caloric restriction in aged long-lived nonhuman primates. Proc Natl Acad Sci USA 2006,103(51),19448-19453","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccell.2016.06.005","volume":"30","author":"Di Biase S.","year":"2016","unstructured":"Di Biase S.; Lee C.; Brandhorst S.; Manes B.; Buono R.; Cheng C.W.; Cacciottolo M.; Martin-Montalvo A.; de Cabo R.; Wei M.; Morgan T.E.; Longo V.D.; Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell 2016,30(1),136-146","journal-title":"Cancer Cell"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00262-014-1542-y","volume":"63","author":"Farazi M.","year":"2014","unstructured":"Farazi M.; Nguyen J.; Goldufsky J.; Linnane S.; Lukaesko L.; Weinberg A.D.; Ruby C.E.; Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. Cancer Immunol Immunother 2014,63(6),615-626","journal-title":"Cancer Immunol Immunother"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2019.07.049","volume":"178","author":"Collins N.","year":"2019","unstructured":"Collins N.; Han S.J.; Enamorado M.; Link V.M.; Huang B.; Moseman E.A.; Kishton R.J.; Shannon J.P.; Dixit D.; Schwab S.R.; Hickman H.D.; Restifo N.P.; McGavern D.B.; Schwartzberg P.L.; Belkaid Y.; The bone marrow protects and optimizes immunological memory during dietary restriction. Cell 2019,178(5),1088-1101","journal-title":"Cell"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"164","DOI":"10.18632\/aging.101382","volume":"10","author":"Weber D.D.","year":"2018","unstructured":"Weber D.D.; Aminazdeh-Gohari S.; Kofler B.; Ketogenic diet in cancer therapy. Aging (Albany NY) 2018,10(2),164-165","journal-title":"Aging (Albany NY)"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3390\/ijerph110202092","volume":"11","author":"Paoli A.","year":"2014","unstructured":"Paoli A.; Ketogenic diet for obesity: Friend or foe? Int J Environ Res Public Health 2014,11(2),2092-2107","journal-title":"Int J Environ Res Public Health"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-15-0916","volume":"22","author":"Martuscello R.T.","year":"2016","unstructured":"Martuscello R.T.; Vedam-Mai V.; McCarthy D.J.; Schmoll M.E.; Jundi M.A.; Louviere C.D.; Griffith B.G.; Skinner C.L.; Suslov O.; Deleyrolle L.P.; Reynolds B.A.; A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma. Clin Cancer Res 2016,22(10),2482-2495","journal-title":"Clin Cancer Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.molmet.2019.06.026","volume":"33","author":"Weber D.D.","year":"2020","unstructured":"Weber D.D.; Aminzadeh-Gohari S.; Tulipan J.; Catalano L.; Feichtinger R.G.; Kofler B.; Ketogenic diet in the treatment of cancer - Where do we stand? Mol Metab 2020,33,102-121","journal-title":"Mol Metab"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1667\/RR14668.1","volume":"187","author":"Zahra A.","year":"2017","unstructured":"Zahra A.; Fath M.A.; Opat E.; Mapuskar K.A.; Bhatia S.K.; Ma D.C.; Rodman S.N.; Snyders T.P.; Chenard C.A.; Eichenberger-Gilmore J.M.; Bodeker K.L.; Ahmann L.; Smith B.J.; Vollstedt S.A.; Brown H.A.; Hejleh T.A.; Clamon G.H.; Berg D.J.; Szweda L.I.; Spitz D.R.; Buatti J.M.; Allen B.G.; Consuming a ketogenic diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: The university of iowa experience of two phase 1 clinical trials. Radiat Res 2017,187(6),743-754","journal-title":"Radiat Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"560","author":"Hopkins B.D.","year":"2018","unstructured":"Hopkins B.D.; Pauli C.; Du X.; Wang D.G.; Li X.; Wu D.; Amadiume S.C.; Goncalves M.D.; Hodakoski C.; Lundquist M.R.; Bareja R.; Ma Y.; Harris E.M.; Sboner A.; Beltran H.; Rubin M.A.; Mukherjee S.; Cantley L.C.; Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 2018,560(7719),499-503","journal-title":"Nature"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12885-016-2337-7","volume":"16","author":"Lussier D.M.","year":"2016","unstructured":"Lussier D.M.; Woolf E.C.; Johnson J.L.; Brooks K.S.; Blattman J.N.; Scheck A.C.; Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer 2016,16(1),310","journal-title":"BMC Cancer"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"e1445","DOI":"10.7759\/cureus.1445","volume":"9","year":"2017","unstructured":"\u0130yikesici, M.S.; Slocum, A.K.; Slocum, A.; Berkarda, F.B.; Kalamian, M.; Seyfried, T.N. Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast cancer. Cureus 2017,9(7),e1445","journal-title":"Cureus"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1758835919853958","DOI":"10.1177\/1758835919853958","volume":"11","author":"van der Louw E.J.T.M.","year":"2019","unstructured":"van der Louw E.J.T.M.; Olieman J.F.; van den Bemt P.M.L.A.; Bromberg J.E.C.; Oomen-de Hoop E.; Neuteboom R.F.; Catsman-Berrevoets C.E.; Vincent A.J.P.E.; Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: A feasibility and safety study. Ther Adv Med Oncol 2019,11,1758835919853958","journal-title":"Ther Adv Med Oncol"},{"key":"ref=89","first-page":"1263","volume":"15","author":"Santos J.G.","year":"2018","unstructured":"Santos J.G.; Da Cruz W.M.S.; Sch\u00f6nthal A.H.; Salazar M.D.; Fontes C.A.P.; Quirico-Santos T.; Da Fonseca C.O.; Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma. Oncol Lett 2018,15(1),1263-1270","journal-title":"Oncol Lett"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7554\/eLife.62420","volume":"9","author":"Drijvers J.M.","year":"2020","unstructured":"Drijvers J.M.; Sharpe A.H.; Haigis M.C.; The effects of age and systemic metabolism on anti-tumor T cell responses. eLife 2020,9,9","journal-title":"eLife"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/1078-0432.CCR-18-0980","volume":"24","author":"Orillion A.","year":"2018","unstructured":"Orillion A.; Damayanti N.P.; Shen L.; Adelaiye-Ogala R.; Affronti H.; Elbanna M.; Chintala S.; Ciesielski M.; Fontana L.; Kao C.; Elzey B.D.; Ratliff T.L.; Nelson D.E.; Smiraglia D.; Abrams S.I.; Pili R.; Dietary protein restriction reprograms tumor-associated macrophages and enhances immunotherapy. Clin Cancer Res 2018,24(24),6383-6395","journal-title":"Clin Cancer Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"E684","DOI":"10.3390\/nu12030684","volume":"12","author":"Wanders D.","year":"2020","unstructured":"Wanders D.; Hobson K.; Ji X.; Methionine restriction and cancer biology. Nutrients 2020,12(3),E684","journal-title":"Nutrients"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41586-019-1437-3","volume":"572","author":"Gao X.","year":"2019","unstructured":"Gao X.; Sanderson S.M.; Dai Z.; Reid M.A.; Cooper D.E.; Lu M.; Richie J.P.; Ciccarella A.; Calcagnotto A.; Mikhael P.G.; Mentch S.J.; Liu J.; Ables G.; Kirsch D.G.; Hsu D.S.; Nichenametla S.N.; Locasale J.W.; Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature 2019,572(7769),397-401","journal-title":"Nature"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ccell.2020.04.005","volume":"37","author":"Tajan M.","year":"2020","unstructured":"Tajan M.; Vousden K.H.; Dietary approaches to cancer therapy. Cancer Cell 2020,37(6),767-785","journal-title":"Cancer Cell"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1038\/s41388-020-01480-z","volume":"39","author":"Peng H.","year":"2020","unstructured":"Peng H.; Wang Y.; Luo W.; Multifaceted role of branched-chain amino acid metabolism in cancer. Oncogene 2020,39(44),6747-6756","journal-title":"Oncogene"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/MCO.0000000000000430","volume":"21","author":"Ananieva E.A.","year":"2018","unstructured":"Ananieva E.A.; Wilkinson A.C.; Branched-chain amino acid metabolism in cancer. Curr Opin Clin Nutr Metab Care 2018,21(1),64-70","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1113\/JP275075","volume":"596","author":"Cummings N.E.","year":"2018","unstructured":"Cummings N.E.; Williams E.M.; Kasza I.; Konon E.N.; Schaid M.D.; Schmidt B.A.; Poudel C.; Sherman D.S.; Yu D.; Arriola Apelo S.I.; Cottrell S.E.; Geiger G.; Barnes M.E.; Wisinski J.A.; Fenske R.J.; Matkowskyj K.A.; Kimple M.E.; Alexander C.M.; Merrins M.J.; Lamming D.W.; Restoration of metabolic health by decreased consumption of branched-chain amino acids. J Physiol 2018,596(4),623-645","journal-title":"J Physiol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e70309","DOI":"10.1371\/journal.pone.0070309","volume":"8","author":"Iwasa M.","year":"2013","unstructured":"Iwasa M.; Kobayashi Y.; Mifuji-Moroka R.; Hara N.; Miyachi H.; Sugimoto R.; Tanaka H.; Fujita N.; Gabazza E.C.; Takei Y.; Branched-chain amino acid supplementation reduces oxidative stress and prolongs survival in rats with advanced liver cirrhosis. PLoS One 2013,8(7),e70309","journal-title":"PLoS One"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3177\/jnsv.61.433","volume":"61","author":"Iwasa M.","year":"2015","unstructured":"Iwasa M.; Sugimoto R.; Ishihara T.; Sekoguchi-Fujikawa N.; Yoshikawa K.; Mifuji-Moroka R.; Tanaka H.; Kobayashi Y.; Hasegawa H.; Takei Y.; Usefulness of levocarnitine and\/or branched-chain amino acids during invasive treatment for hepatocellular carcinoma. J Nutr Sci Vitaminol (Tokyo) 2015,61(6),433-440","journal-title":"J Nutr Sci Vitaminol (Tokyo)"}],"container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389203723666220620161742","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/206224\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389203723666220620161742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T07:46:57Z","timestamp":1670744817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/206224\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389203723666220620161742","relation":{},"ISSN":["1389-2037"],"issn-type":[{"type":"print","value":"1389-2037"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}